A Phase 1, Multicenter, Open-label, Multiple Dose escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects with Advanced Cancers with HER2 Expression
- Markman, Ben (Primary Chief Investigator (PCI))
- Frentzas, Sophia (Primary Chief Investigator (PCI))
Project: Research